Dendreon/Corvas merger in peril?
Executive Summary
Several large Corvas shareholders oppose acquisition by Dendreon, maintaining that deal does not fairly value company. One proposal would liquidate the company ("The Pink Sheet" March 3, p. 25)...
You may also be interested in...
Biotech Startups Trading IPO Filings For Selling Block – BIO Panel
The goal of a biotech startup appears to have shifted away from a focus on entering the public market through an IPO in favor of building the company to become an acquisition target
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.